BIOMAT Database Logo BIOMAT Database Logo

Small bowel enteropathy associated with olmesartan medoxomil treatment. 2017

Michail Galanopoulos, and Lazaros Varytimiadis, and Athanasios Tsigaridas, and Pantelis S Karatzas, and Emmanuel Archavlis, and Nikos Viazis, and Christina Vourlakou, and Gerassimos J Mantzaris
Department of Gastroenterology (Michail Galanopoulos, Lazaros Varytimiadis, Athanasios Tsigaridas, Pantelis S. Karatzas, Emmanuel Archavlis, Nikos Viazis, Gerassimos J. Mantzaris).

Sprue-like enteropathy associated with treatment with olmesartan medoxomil, an angiotensin II receptor blocker, has been described recently. Herein, we report two patients who developed chronic severe non-bloody diarrhea, weight loss, and muscle wasting after prolonged use of olmesartan. Histologic and immunohistochemical examination of multiple duodenal biopsies revealed severe villous atrophy. Clinical signs ceased upon drug discontinuation. Physicians should be aware of this enteropathy even if olmesartan has been taken for months or years. Whether this adverse event is specific for olmesartan or is a class effect of angiotensin II receptor blockers is currently unknown. To the best of our knowledge, these case reports are the first reported in Greece.

UI MeSH Term Description Entries

Related Publications

Michail Galanopoulos, and Lazaros Varytimiadis, and Athanasios Tsigaridas, and Pantelis S Karatzas, and Emmanuel Archavlis, and Nikos Viazis, and Christina Vourlakou, and Gerassimos J Mantzaris
[Severe enteropathy with villous atrophy olmesartan medoxomil-associated].
January 2013, Therapie,
Michail Galanopoulos, and Lazaros Varytimiadis, and Athanasios Tsigaridas, and Pantelis S Karatzas, and Emmanuel Archavlis, and Nikos Viazis, and Christina Vourlakou, and Gerassimos J Mantzaris
Enteropathy Associated with Olmesartan.
January 2016, GE Portuguese journal of gastroenterology,
Michail Galanopoulos, and Lazaros Varytimiadis, and Athanasios Tsigaridas, and Pantelis S Karatzas, and Emmanuel Archavlis, and Nikos Viazis, and Christina Vourlakou, and Gerassimos J Mantzaris
Olmesartan-associated enteropathy.
July 2017, Proceedings (Baylor University. Medical Center),
Michail Galanopoulos, and Lazaros Varytimiadis, and Athanasios Tsigaridas, and Pantelis S Karatzas, and Emmanuel Archavlis, and Nikos Viazis, and Christina Vourlakou, and Gerassimos J Mantzaris
[Olmesartan-associated Enteropathy].
December 2021, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
Michail Galanopoulos, and Lazaros Varytimiadis, and Athanasios Tsigaridas, and Pantelis S Karatzas, and Emmanuel Archavlis, and Nikos Viazis, and Christina Vourlakou, and Gerassimos J Mantzaris
Olmesartan medoxomil.
January 2002, Drugs,
Michail Galanopoulos, and Lazaros Varytimiadis, and Athanasios Tsigaridas, and Pantelis S Karatzas, and Emmanuel Archavlis, and Nikos Viazis, and Christina Vourlakou, and Gerassimos J Mantzaris
Olmesartan-Induced Spruelike Enteropathy: An Emerging Cause of Small Bowel Injury.
July 2020, Cureus,
Michail Galanopoulos, and Lazaros Varytimiadis, and Athanasios Tsigaridas, and Pantelis S Karatzas, and Emmanuel Archavlis, and Nikos Viazis, and Christina Vourlakou, and Gerassimos J Mantzaris
Severe spruelike enteropathy associated with olmesartan.
August 2012, Mayo Clinic proceedings,
Michail Galanopoulos, and Lazaros Varytimiadis, and Athanasios Tsigaridas, and Pantelis S Karatzas, and Emmanuel Archavlis, and Nikos Viazis, and Christina Vourlakou, and Gerassimos J Mantzaris
Olmesartan medoxomil/amlodipine.
January 2009, Drugs,
Michail Galanopoulos, and Lazaros Varytimiadis, and Athanasios Tsigaridas, and Pantelis S Karatzas, and Emmanuel Archavlis, and Nikos Viazis, and Christina Vourlakou, and Gerassimos J Mantzaris
Olmesartan-associated enteropathy: Belgian survey.
January 2021, Therapie,
Michail Galanopoulos, and Lazaros Varytimiadis, and Athanasios Tsigaridas, and Pantelis S Karatzas, and Emmanuel Archavlis, and Nikos Viazis, and Christina Vourlakou, and Gerassimos J Mantzaris
Immunopathogenesis of olmesartan-associated enteropathy.
December 2015, Alimentary pharmacology & therapeutics,
Copied contents to your clipboard!